Replies to post #2288 on Lisata Therapeutics Inc (LSTA)

[lunatick]

I think that the comparison of the two other biotechnology companies should only show how undervalued CLBS is.
NWBO 52 Week Low was $3.79
I believe, the increase in the share price of NWBO is also due to the purchase of Woodford's equity funds.
However, an investment fund can be mistaken, but it has created a great deal of confidence.
Also the support from its shareholders in the discussion forums is very strong. and I finally have to admit that I am convinced even by the company and the management.

I think that CLBS with it's slow share price, is still not interesting for an investment fund.
We are likely to win only through positive publicity, interviews, meetings, etc. or a partnership.
It would be nice if we knew what the management continues to plan for the future, for example further studies regarding NBS20.